Dianthus Therapeutics DNTH
$84.55 −$0.28 (-0.33%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $84.08 -0.56%
Open$83.62
Prev close$84.83
Day range$82.53 – $85.67
Volume799.7K
Market cap$4.76B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$1.21M+205.6% YoY
Operating profit-$58.47M-45.1% YoY
Net profit-$46.64M-26.9% YoY
Diluted EPS-$0.81+16.5% YoY
Free cash flow-$50.70M-65.9% YoY
Operating cash flow-$50.33M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin-8,683.9%
Net margin-7,436.5%
Return on equity-22.6%
Return on assets-21.8%
Return on invested capital-26.5%
Current ratio30.02
Liabilities / assets2.7%
Cash & investments$837.78M
Total debt$859,000.00
Net cash (debt)$836.92M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $1.21M | $761,000.00 | $463,000.00 | $2.04M | $284,000.00 |
| Total Operating Revenue | $1.21M | $761,000.00 | $463,000.00 | $2.04M | $284,000.00 |
| Operating Expense | $59.68M | $62.24M | $47.00M | $179.97M | $69.83M |
| Selling and Admin Expenses | $14.08M | $13.56M | $12.47M | $34.33M | $9.93M |
| -General & Admin Expense | $14.08M | $13.56M | $12.47M | $34.33M | $9.93M |
| Research & Development | $45.60M | $48.69M | $34.53M | $145.64M | $59.90M |
| Operating Profit | -$58.47M | -$61.48M | -$46.53M | -$177.93M | -$69.54M |
| Net Non-Operating Interest Income (Expense) | $12.14M | $11.54M | $6.27M | $16.12M | $5.27M |
| Non-Operating Interest Income | $12.14M | $11.54M | $6.27M | $16.12M | $5.27M |
| Other Income (Expense) | -$314,000.00 | -$275,000.00 | -$566,000.00 | -$523,000.00 | -$158,000.00 |
| Gain on Sale of Security | $4,000.00 | $95,000.00 | -$317,000.00 | $451,000.00 | $251,000.00 |
| Other Non-Operating Income (Expenses) | -$318,000.00 | -$370,000.00 | -$249,000.00 | -$974,000.00 | -$409,000.00 |
| Pretax Profit | -$46.64M | -$50.22M | -$40.83M | -$162.34M | -$64.43M |
| Net Profit | -$46.64M | -$50.22M | -$40.83M | -$162.34M | -$64.43M |
| Profit from Continuing Operations | -$46.64M | -$50.22M | -$40.83M | -$162.34M | -$64.43M |
| Net Income to Parent Company | -$46.64M | -$50.22M | -$40.83M | -$162.34M | -$64.43M |
| Net Income to Common Stockholders | -$46.64M | -$50.22M | -$40.83M | -$162.34M | -$64.43M |
| Basic EPS | -$0.81 | -$0.90 | -$0.85 | -$4.20 | -$1.43 |
| Diluted EPS | -$0.81 | -$0.90 | -$0.85 | -$4.20 | -$1.43 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.28B | $1.21B | $1.25B | $530.92M | $530.92M |
| Total Current Assets | $856.04M | $897.54M | $1.12B | $409.44M | $409.44M |
| Cash and Cash Equivalents & Short-Term Investments | $837.78M | $886.81M | $1.11B | $404.30M | $404.30M |
| -Cash and Cash Equivalents | $55.69M | $110.55M | $627.67M | $51.09M | $51.09M |
| -Short Term Investments | $782.10M | $776.26M | $483.59M | $353.21M | $353.21M |
| Receivables | $582,000.00 | $106,000.00 | $1.23M | $52,000.00 | $52,000.00 |
| -Accounts Receivable | $582,000.00 | $106,000.00 | $1.23M | $52,000.00 | $52,000.00 |
| Prepaid Assets | $17.50M | $10.43M | $7.34M | $5.01M | $5.01M |
| Other Current Assets | $169,000.00 | $184,000.00 | $83,000.00 | $86,000.00 | $86,000.00 |
| Total Non-Current Assets | $420.21M | $315.73M | $126.97M | $121.48M | $121.48M |
| Net PPE | $1.90M | $1.64M | $1.57M | $1.63M | $1.63M |
| -Gross PPE | $2.31M | $2.01M | $1.90M | $1.94M | $1.94M |
| -Accumulated Depreciation | -$410,000.00 | -$373,000.00 | -$336,000.00 | -$304,000.00 | -$304,000.00 |
| Investments and Advances | $406.04M | $303.63M | $113.87M | $110.14M | $110.14M |
| -Available for Sale Securities | $406.04M | $303.63M | $113.87M | $110.14M | $110.14M |
| Other Non-Current Assets | $12.27M | $10.46M | $11.54M | $9.72M | $9.72M |
| Total Liabilities | $34.82M | $41.25M | $45.57M | $37.52M | $37.52M |
| Total Current Liabilities | $28.52M | $34.39M | $38.28M | $30.73M | $30.73M |
| Payables | $5.50M | $6.39M | $5.27M | $9.73M | $9.73M |
| -Accounts Payable | $5.50M | $6.39M | $5.27M | $9.73M | $9.73M |
| Current Accrued Expenses | $13.55M | $20.49M | $28.43M | $9.94M | $9.94M |
| Short-Term Debt and Capital Lease Obligation | $349,000.00 | $374,000.00 | $399,000.00 | $367,000.00 | $367,000.00 |
| -Current Capital Lease Obligation | $349,000.00 | $374,000.00 | $399,000.00 | $367,000.00 | $367,000.00 |
| Current Deferred Liabilities | $1.59M | $1.52M | $1.49M | $1.19M | $1.19M |
| Total Non-Current Liabilities | $6.31M | $6.86M | $7.29M | $6.79M | $6.79M |
| Long Term Debt and Capital Lease Obligation | $859,000.00 | $913,000.00 | $965,000.00 | $1.02M | $1.02M |
| -Long Term Capital Lease Obligation | $859,000.00 | $913,000.00 | $965,000.00 | $1.02M | $1.02M |
| Non-Current Deferred Liabilities | $5.45M | $5.94M | $6.32M | $5.77M | $5.77M |
| Total Equity | $1.24B | $1.17B | $1.20B | $493.40M | $493.40M |
| Stockholders' Equity | $1.24B | $1.17B | $1.20B | $493.40M | $493.40M |
| Capital Stock | $56,000.00 | $55,000.00 | $54,000.00 | $43,000.00 | $43,000.00 |
| -Common Stock | $56,000.00 | $55,000.00 | $54,000.00 | $43,000.00 | $43,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.72B | $1.60B | $1.58B | $829.60M | $829.60M |
| Retained Earnings | -$474.42M | -$427.78M | -$377.56M | -$336.73M | -$336.73M |
| Gains/Losses Not Affecting Retained Earnings | -$6.28M | -$2.13M | -$575,000.00 | $489,000.00 | $489,000.00 |
| -Due from Related Parties Current | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$50.33M | -$48.98M | -$28.86M | -$129.06M | -$46.98M |
| Net cash flow from continuing operations | -$50.33M | -$48.98M | -$28.86M | -$129.06M | -$46.98M |
| Net Income from Continuing Operations | -$46.64M | -$50.22M | -$40.83M | -$162.34M | -$64.43M |
| Gain/Loss from Continuing Operations | -$28,000.00 | -$105,000.00 | $302,000.00 | -$507,000.00 | -$253,000.00 |
| Depreciation & Depletion & Amortization | $109,000.00 | $107,000.00 | $76,000.00 | $428,000.00 | $97,000.00 |
| Change in Working Capital | -$15.61M | -$5.01M | $2.22M | $16.73M | $12.48M |
| -Change in Receivables | -$476,000.00 | $1.12M | -$1.18M | $755,000.00 | $4.95M |
| -Change in Prepaid Assets | -$7.06M | -$3.20M | -$2.33M | -$235,000.00 | $1.12M |
| -Change in Payables and Accrued Expense | -$5.99M | -$3.78M | $7.00M | $11.28M | $6.68M |
| -Change in Other Current Assets | -$1.66M | $1.18M | -$2.12M | $358,000.00 | -$207,000.00 |
| -Change In Other Working Capital | -$430,000.00 | -$339,000.00 | $849,000.00 | $4.57M | -$64,000.00 |
| Net cash flow from investing | -$111.87M | -$478.52M | -$133.97M | -$122.83M | $37.20M |
| Net Cash Flow from Continuing Investing Activities | -$111.87M | -$478.52M | -$133.97M | -$122.83M | $37.20M |
| Capital Expenditure | -$368,000.00 | -$181,000.00 | -$10,000.00 | -$213,000.00 | -$138,000.00 |
| Net Investment Purchase and Sale | -$111.51M | -$478.34M | -$133.96M | -$122.62M | $37.34M |
| Financing Cash Flow | $107.47M | $10.38M | $739.41M | $280.13M | $4.88M |
| Net Cash Flow from Continuing Financing Activities | $107.47M | $10.38M | $739.41M | $280.13M | $4.88M |
| Net Common Stock Issuance | $98.07M | $0.00 | $736.36M | $272.27M | $0.00 |
| Proceeds from Stock Option Exercised | $9.41M | $10.58M | $4.40M | $8.22M | $5.08M |
| Net Other Financing Charges | $0.00 | -$201,000.00 | -$1.34M | -$364,000.00 | -$192,000.00 |
| Ending Cash Balance | $55.98M | $110.72M | $627.84M | $51.25M | $51.25M |
| Net Change in Cash | -$54.74M | -$517.12M | $576.58M | $28.23M | -$4.90M |
| Beginning Cash Balance | $110.72M | $627.84M | $51.25M | $23.02M | $56.15M |
| Free Cash Flow | -$50.70M | -$49.16M | -$28.87M | -$129.27M | -$47.12M |
No comments yet — be the first to weigh in on DNTH.
Sign in to join the discussion.